Pharmacological characterization of PD 152255, a novel dimeric benzimidazole dopamine D3 antagonist

Pharmacology Biochemistry and Behavior

Volumn 59, Issue 2, 1998, Pages 487-493

  Corbin, Ann E ^a   Pugsley, Thomas A ^a   Akunne, Hyacinth C ^a   Whetzel, Steven Z ^a   Zoski, Kim T ^a   Georgic, Lynn M ^a   Nelson, Carrie B ^a   Wright, Jon L ^a   Wise, Lawrence D ^a   Heffner, Thomas G ^a  

^a PFIZER INC   (United States)

Author keywords

Antipsychotic; Depamine D3 receptors; Dopamine D3 antagonist; Locomotor activity

Indexed keywords

BENZIMIDAZOLE; DOPAMINE; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER RECEPTOR; PD 152255; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GUINEA PIG; IN VITRO STUDY; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZIMIDAZOLES; BIOGENIC MONOAMINES; BRAIN CHEMISTRY; CHO CELLS; CHOLINERGIC ANTAGONISTS; CRICETINAE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MOTOR ACTIVITY; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SIGNAL TRANSDUCTION; THYMIDINE;

EID: 0032004949     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00442-5     Document Type: Article

References (36)

1. Ahlenius S., Salmi P. Behavioral and biochemical effects of the dopamine D3 receptor-selective ligand, 7-OH-DPAT, in the normal and the reserpine-treated rat. Eur. J. Pharmacol. 260:1994;177-181.
2. Arnt J. Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of d-amphetamine. Eur. J. Pharmacol. 283:1995;55-62.
3. Baldessarini R. J., Tarsy D. Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs. Annu. Rev. Neurosci. 3:1980;23-41.
4. 3H]-SCH 23390, a selective D-1 receptor agonist ligand in rat brain. Life Sci. 35:1984;1885-1893.
5. Bouthenet M.-L., Souil E., Martres M.-P., Sokoloff P., Giros B., Schwartz J.-C. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry. Comparison with dopamine D2 receptor mRNA Brain Res. 564:1991;203-219.
6. Caine S. B., Koob G. F. Modulation of cocaine self-administration in the rat through D3 dopamine receptors. Science. 260:1993;1814-1816.
7. Carlsson A., Kehr W., Lindqvist M. Agonist/antagonist interaction on dopamine receptors in brain, as reflected in rate of tyrosine and tryptophan hydroxylation. J. Neural Transm. 40:1975;99-113.
8. Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am. J. Psychiatry. 135:1978;164-173.
9. Chio C. L., Lajiness M. E., Huff R. M. Activation of heterologously expressed D3 dopamine receptors. Comparison with D2 dopamine receptors Mol. Pharmacol. 45:1994;51-60.
10. Corbin A. E., Wiley J. N., Heffner T. G. Possible involvement of dopamine D3 autoreceptors in the behavioral effects of PD 128907. Soc. Neurosci. Abstr. 20:1994;1356.
11. Daly S. A., Waddington J. L. Behavioral effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other "D2-like" agonists. Neuropharmacology. 32:1993;509-510.
12. Damsma G., Bottema T., Westerink B. H. C., Tepper P., Dijkstra D., Pugsley T. A., MacKenzie R. G., Heffner T. G., Wikström H. Pharmacological aspects of R-(+)-7-OH-DPAT, a putative dopamine D3 receptor ligand. Eur. J. Pharmacol. 249:1993;R9-R10.
13. Gobert A., Rivet J.-M., Audinot V., Cistarelli L., Spedding M., Vian J., Peglion J.-L., Millan M. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297. II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways J. Pharmacol. Exp. Ther. 275:1995;899-913.
14. Heffner T. G., Wiley J. N., Williams A. E., Bruns R. F., Coughenour L. L., Downs D. A. Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice. Psychopharmacology (Berlin). 98:1989;31-37.
15. Landwehrmeyer B., Mengod G., Palacios J. M. Dopamine D3 receptor mRNA and binding sites in human brain. Mol. Brain Res. 18:1993;187-192.
16. 3H]-1-[1-(2-thienyl)cyclohexyl]piperidine. J. Pharmacol. Exp. Ther. 238:1986;739-748.
17. Largent B. L., Wikström H., Snowman A. M., Snyder S. H. Novel antipsychotic drugs share high affinity for sigma receptors. Eur. J. Pharmacol. 155:1988;345-347.
18. Lundeen J. E., Gordon J. H. Computer analysis of binding data. O'Brien R. A. Receptor binding in drug research. 1986;31-49 Marcel Dekker, New York.
19. Meador-Woodruff J. H., Grandy D. K., Van Tol H. H. M., Damask S. P., Little K. Y., Civelli O., Watson S. J. Dopamine receptor gene expression in the human medial temporal lobe. Neuropsychopharmacology. 10:1994;239-248.
20. Meller E., Bohmaker K., Goldstein M., Basham D. A. Evidence that striatal synthesis-inhibiting autoreceptors are dopamine D3 receptors. Eur. J. Pharmacol. 249:1993;R5-R6.
21. Meltzer H. Y., Stahl S. M. The dopamine hypothesis of schizophrenia. A review Schizophren. Bull. 2:1976;19-76.
22. Millan M. J., Peglion J.-L, Vian J., Rivet J.-M., Brocco M., Gobert A., Newman-Tancrede A., Dacquet C., Bervoets K., Girardon S., Jacques V., Chaput C., Audinot V. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297. I. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy J. Pharmacol. Exp. Ther. 275:1995;885-898.
23. Munson P. J., Rodbard D. LIGAND. A versatile computerized approach to characterization of ligand-binding systems Anal. Biochem. 107:1980;220-239.
24. O'Dowd B. F. Structures of dopamine receptors. J. Neurochem. 60:1993;804-816.
25. Pugsley T. A., Davis M. D., Akunne H. C., MacKenzie R. G., Shih Y.-H., Damsma G., Wikström H., Whetzel S. Z., Cooke L. W., Georgic L. M., DeMattos S. B., Corbin A. E., Wise L. D., Dijkstra D., Heffner T. G. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J. Pharmacol. Exp. Ther. 275:1995;1355-1366.
26. Sautel F., Griffon N., Sokoloff P., Schwartz J.-C., Launay C., Simon P., Costentin J., Schoenfelder A., Garrido F., Mann A., Wermuth C. G. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J. Pharmacol. Exp. Ther. 275:1995;1239-1246.
27. Schwarz R. D., Spencer C. J., Jaen J. C., Mirzadegan T., Moreland D., Tecle H., Thomas A. J. Mutations of aspartate 103 in the Hm2 receptor and alterations in receptor binding properties of muscarinic agonists. Life Sci. 56:1995;923-929.
28. 4.2 receptor on CHO K1 cells. Soc. Neurosci. Abstr. 21:1995;621.
29. 2L chimeras (COS-7 cells). Prog. Neuro-psychopharmacol. & Biol. Psychiat. 21:1997;153-167.
30. Sibley D. R., Monsma F. J. Molecular biology of dopamine receptors. Trends Pharmacol. Sci. 13:1992;61-69.
31. Sokoloff P., Giros B., Martres M.-P., Bouthenet N.-L., Schwartz J.-C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 347:1990;146-151.
32. Svensson K., Johansson A. M., Magnusson T., Carlsson A. AJ 76 and (+)-UH 232. Central stimulants acting as preferential dopamine autoreceptor antagonists Naunyn-Schmiedeberg's Arch. Pharmacol. 334:1986;234-245.
33. Svensson K., Carlsson A., Waters N. Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release. J. Neural. Transm. [Gen Sect]. 95:1994;71-74.
34. Tallarida R. J., Murray R. B. Pharm/PCS version 4.2, a pharmacologic calculation system based on manual of pharmacologic calculations with computer programs. 2:1986;Springer- Verlag, New York.
35. Waters N., Svensson K., Haadsma-Svensson S. R., Smith M. W., Carlsson A. The dopamine D3-receptor. A postsynaptic receptor inhibitory on rat locomotor activity J. Neural Transm. [Gen Sect]. 94:1993;11-19.
36. Wright J., Downing D., Heffner T., Pugsley T., MacKenzie R., Wise L. Discovery of selective dopamine D3 ligands; I. Dimeric 2-[4-(3-aminopropoxy)phenyl]benzimidazole antagonists. Bioorg. Med. Chem. Lett. 5:1995;2541-2546.